Reply  by Oderich, Gustavo S. & Tallarita, Tiziano
LETTERS TO THE EDITOR
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iRegarding “Outcomes of carotid artery stenting
versus historical surgical controls for
radiation-induced carotid stenosis”
We read with interest the peri-operative results of Tallarita et
al1 with regards to intervention in asymptomatic postradiotherapy
carotid artery stenosis (CAS).
Any intervention in asymptomatic postradiotherapy CAS is, as
the authors acknowledge, controversial. We note that 47% of
patients in the study were asymptomatic.1 The indication for
surgery or stenting for CAS, whether symptomatic or asymptom-
atic, is based upon the intervention reducing long-term risk of
stroke compared with best medical therapy. In addition, proce-
dural risks must be suitably low for intervention to be justified.
In asymptomatic patients, the Asymptomatic Carotid Athero-
sclerosis Study2 and the Asymptomatic Carotid Surgery Trial3,4
studies demonstrated that the benefit of carotid endarterectomy in
asymptomatic patients is mainly dependent upon patient life ex-
pectancy.
In patients who have had neck radiotherapy, cancer-related
deaths need to be considered, resulting in a lower likelihood that a
patient will survive for long enough to benefit from their carotid
intervention. For example, 57% of patients in this study1 had
laryngeal or nasopharyngeal cancer. Absolute 5-year period sur-
vival is 60.6% and 61.5%, respectively.5,6 Relative to the healthy
American population, 5-year survival rates for regional and local-
ized laryngeal cancer are 41.6% and 76.7%, respectively.5 For
nasopharyngeal cancer, it is 55.7% and 82.3%, respectively.6 In
essence, these patients are far less likely to survive to 5 years to
benefit from carotid intervention because of cancer-specific death.
In the study by Tallarita and colleagues, the main cause of late
death (median, 58 months) across both groups was malignancy,
responsible for the death of approximately 30% of patients in the
CAS group and 16% of patients in the surgery group.1 This is
particularly important in the patients selected for CAS, where the
5-year survival was reported as 40%  9%.
Therefore, clinicians should be aware of these statistics
when considering surgery or stenting in the context of asymp-
tomatic carotid stenosis postradiotherapy. Assessment of a pa-
tient’s life expectancy based on the type and stage of cancer5,6 in
conjunction with an oncologist is essential. If it is deemed that
intervention is suitable given the individual patient’s prognosis,
it is then that the question of which intervention is appropriate
should be raised.
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Important observations were raised regarding the indication
f carotid interventions in asymptomatic patients with radiation-
nduced carotid stenosis (RICS). In our study, 5-year patient
urvival was 100% for open surgery and only 40% 9% for carotid
rtery stenting (CAS), mostly due to recurrent cancer, indicating
ifferences in patient selection with more liberal use of CAS in the
ast few years.1 Indeed, malignancy accounted for 13 of the 14 late
eaths (93%) in the entire cohort, while only one patient (7%) died
f stroke. There were no peri-procedural deaths, and early neuro-
ogical events occurred in 3% of open surgical and 6% of CAS
atients. Freedom from any neurologic events at 5 years was 100%
or open surgery and 90%  7% for CAS (P  .06). While these
esults indicate high risk of cancer-related death among RICS
atients treated by CAS, it also shows that both methods of carotid
evascularization were performed with no mortality, and with low
isk of peri-procedural events, albeit with a trend towards improved
troke protection for open surgery.
The natural history of asymptomatic RICS is not well
efined. However, Dorresteijn and colleagues2 indicated that
% of 367 patients treated by head and neck irradiation for
ancer developed stroke over 7 years, whereas the expected
troke rate is only 0.6% in the general population during the
ame period. In addition, the authors have not analyzed
hether patients had evidence of RICS, indicating that stroke
ates may be even higher in the subset of patients who have high
rade radiation-induced lesions.
The key questions are whether carotid revascularization
hould be indicated in any patient with asymptomatic RICS,
otably a higher risk group for neurological events and for death,
nd whether carotid revascularization is effective in preventing
trokes in these patients. Cheng and associates3 reported that
arotid stenosis progress more rapidly and more significantly in
adiated arteries compared with nonradiated arteries. In that study,
nnual progression rates were 15% for radiated and 5% for nonra-
iated arteries. At a mean follow up of 3 years, 43% of patients with
adiated arteries had progressed to stenoses 50%. The results of
he Asymptomatic Carotid Atherosclerosis Study4 and Asymptom-
tic Carotid Surgery Trial5 studies apply primarily to good risk
atients with nonradiated lesions, and not necessarily to patients
ith RICS. Nevertheless, the observations raised are of paramount
mportance on the decision-making of whether to proceed with
arotid intervention in any patient with RICS, recognizing the
everal of these patients may have limited life expectancy on the
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Volume 54, Number 6 Letters to the Editor 1869basis of their underlying malignancy. Unfortunately, our study
does not provide definitive answers to the above-mentioned ques-
tions, but confirms that survival was low in the overall cohort, and
that CAS was performed with low peri-procedural risk but with
high restenoses rates. We continue to indicate carotid revascular-
ization after a careful discussion of our institutional results, the
risks of stroke or stroke-related disability, the patients overall
prognosis, and the anatomical characteristics of the lesion. In
general, patients with no evidence of recurrent cancer and who are
symptomatic and have suitable anatomy are treated by either CAS
or open surgery, depending on factors such as presence of concom-
itant radical neck dissection, tracheostomy, or skin damage. For
asymptomatic patients, we recognize that the indication of revas-
cularization remains controversial and that one should carefully
analyze the patient’s life expectancy and anatomical risk for the
procedure. However, carotid revascularization continues to have a
role in selective patients with significant progression of the carotid
lesion and no evidence of recurrentmetastatic disease or limited life
expectancy.
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Regarding “Evaluation of the Endurant stent graft
under instructions for use vs off label conditions for
endovascular aortic aneurysm repair”
We read the article by Torsello et al with interest.1 While the
use of endovascular aneurysm repair (EVAR) has revolutionized
the management of infrarenal abdominal aortic aneurysm (AAA)
its use has only been shown feasible in 40% to 60% of AAA.
Advances in technology, imaging, graft design, and operator expe-
rience has lead to an extension of their use beyond initial manufac-
turer’s guidelines. The device studied in this article is licensed to a
10-mm neck extending or rather shortening the previous bench-
mark of 15 mm. Nevertheless, the ability to place the graft at
operation outside this use is shown to be associated with increased
type I endoleak. Numbers did not reach significance as the primary
endpoint frequency was low and study group small.
We have previously shown that use of EVAR outside IFU was
associated with a worse outcome that translated into patient mor-
tality in symptomatic AAA.2 Recently we conducted a review of the
EUROSTAR database of over 75003 cases to determine the long-
term outcome of elective infrarenal endografts inserted outside the
manufacturers’ IFUs. We found a significant association between
a
ehe “off label” use of endografts and the incidence of type 1
ndoleak, which is in agreement with the authors. However, our
ata also showed that grafts placed outside IFU were associated
ith increased all-cause mortality and type I endoleak was
ssociated with increased aneurysm related mortality at long-
erm follow-up. The grafts in our study, however, were older
eneration and did not include the Endurant. These datasets
upport the authors comments that use of EVAR outside IFU
an be done but short-term results that may appear satisfactory
re in fact significantly worse in long-term follow-up.
We suggest that use of devices outside license or recom-
ended usage should be undertaken only in the centers with
obust data collection, or better still, in clinical trials. EVAR is an
xcellent prophylactic treatment for infrarenal AAA when under-
aken correctly, however, it appears less effective if outside IFU and
ncreases the risk for long-term failure. Long-term follow-up of
VAR has shown the early advantages of infrarenal EVARs over
pen surgery disappear with time.4 The consequence of using
off-label” stent grafts may have resulted in steadily increased
umbers of ruptured aneurysms. This has prompted us to resort to
more liberal use of fenestrated stent grafts, given the excellent
arly results with the latter.
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We read with interest the comment of Cross et al and we thank
hem for the attention paid to our article.
We completely agree with the authors that the use of en-
ografts outside the manufacturers’ instructions for use (IFU) was
esponsible of a higher risk of type I endoleak1; our population
tudy did not have the right power to obtain a statistical signifi-
ance, but we explained this bias in the text. Furthermore, our
ollow-up was too short to give rough conclusions.2
Then, we agree with the authors that the applicability of endo-
ascular aneurysm repair outside IFU should be reserved for those
enters with great experience in aortic endovascular procedures.
In other reports, we suggested the use of alternative procedures
fenestrated stent grafts, chimney technique) in selected patients with
long life expectancy and with stable lesions, even if these advanced
ndovascular techniques have still not resolved problems. In fact, the
